2CUREX AB SEK-,10 Aktie Logo
SE0010468124
A2H725
2CUREX.ST

2CUREX AB SEK-,10 Aktie

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics
In 2025, 2CUREX AB SEK-,10 Aktie has already paid €0.0714 in dividends. The last payout was in July 2025.

Financials

In the last year, 2CUREX AB SEK-,10 Aktie had revenue of €0 and net profit of -€241.09K
(EUR) 2025
YoY
Revenue 0 -
Gross profit 0 -
Net profit -241.09K 32.75%
EBITDA -257.26K 28.25%

Fundamentals

Metric Value
Market capitalization
€945.05K
Number of shares
25.1M
52-week high/low
€0.29 - €0.0359
Dividends No
Beta
3.01
P/E ratio
-4.20
PEG ratio
-0.19
P/B ratio
2.07
P/S ratio
0.00

Company profile

2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also conducting various clinical programs for IndiTreat for breast colorectal, ovarian, and pancreatic cancers. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.

Name
2CUREX AB SEK-,10 Aktie
CEO
Nathaniel Hutley
Headquarters Landskrona,
Denmark
Website
IPO
11/24/2017
Employees 14

Ticker symbols

Exchange Symbol
Sto
2CUREX.ST
Frankfurt
2QE.F
Stockholm
2CUREX.ST
München
2QE.MU
🍪

Parqet  uses cookies. Learn more